Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.66 -1.2%	$0.64	$0.51 ▼ $1.80	$62.89M	0.32	668,069 shs	159,138 shs
CEMI Chembio Diagnostics	$0.46	$0.43	$0.19 ▼ $1.24	$16.71M	1.85	661,416 shs	351,642 shs
CLSD Clearside Biomedical	$0.74 -2.8%	$0.85	$0.70 ▼ $1.65	$57.50M	2.11	342,655 shs	111,096 shs
PDSB PDS Biotechnology	$1.41 +2.2%	$1.23	$0.85 ▼ $4.42	$64.45M	1.4	488,040 shs	889,233 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	-4.34%	+3.51%	-12.66%	-32.40%
CEMI Chembio Diagnostics	0.00%	0.00%	0.00%	0.00%	0.00%
CLSD Clearside Biomedical	0.00%	-11.94%	-12.61%	-4.10%	-45.71%
PDSB PDS Biotechnology	0.00%	-13.92%	-1.45%	+12.40%	-54.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.0446 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.8	1.3
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	2.0054 of 5 stars	3.5	5.0	0.0	0.0	1.5	0.0	0.0
PDSB PDS Biotechnology	1.8822 of 5 stars	3.7	3.0	0.0	0.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	318.82% Upside
CEMI Chembio Diagnostics	0.00	N/A	N/A	N/A
CLSD Clearside Biomedical	3.00	Buy	$4.80	548.74% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	538.30% Upside

Current Analyst Ratings Breakdown

Latest CEMI, PDSB, ASRT, and CLSD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/8/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/31/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/27/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $13.00
3/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.50

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$119.00M	0.53	$0.59 per share	1.12	$1.46 per share	0.45
CEMI Chembio Diagnostics	$48.34M	0.35	N/A	N/A	$0.48 per share	0.95
CLSD Clearside Biomedical	$3.76M	15.28	N/A	N/A	($0.25) per share	-2.96
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$331.94M	-$0.32	N/A	21.89	3.25	-54.46%	3.79%	1.81%	8/6/2025 (Estimated)
CEMI Chembio Diagnostics	-$23.29M	-$1.20	N/A	∞	N/A	-47.03%	-113.57%	-38.22%	N/A
CLSD Clearside Biomedical	-$32.49M	-$0.41	N/A	N/A	N/A	-413.83%	N/A	-92.90%	8/11/2025 (Estimated)
PDSB PDS Biotechnology	-$42.94M	-$0.94	N/A	N/A	N/A	N/A	-139.57%	-67.22%	8/12/2025 (Estimated)

Latest CEMI, PDSB, ASRT, and CLSD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/14/2025	Q1 2025	PDSB PDS Biotechnology	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
3/27/2025	Q4 2024	CLSD Clearside Biomedical	-$0.13	-$0.10	+$0.03	-$0.10	$0.27 million	$0.31 million
3/27/2025	Q4 2024	PDSB PDS Biotechnology	-$0.29	-$0.21	+$0.08	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.30	2.01	1.57
CEMI Chembio Diagnostics	N/A	1.23	1.04
CLSD Clearside Biomedical	N/A	4.49	4.49
PDSB PDS Biotechnology	0.55	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CEMI Chembio Diagnostics	8.65%
CLSD Clearside Biomedical	18.75%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CEMI Chembio Diagnostics	3.30%
CLSD Clearside Biomedical	6.20%
PDSB PDS Biotechnology	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	92.42 million	Optionable
CEMI Chembio Diagnostics	337	36.73 million	35.51 million	Not Optionable
CLSD Clearside Biomedical	30	77.71 million	68.87 million	Optionable
PDSB PDS Biotechnology	20	45.71 million	33.86 million	Optionable

CEMI, PDSB, ASRT, and CLSD Headlines

Recent News About These Companies

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2 at 8:00 AM | globenewswire.com

PDS Biotechnology files to sell 9.82M shares of common stock for holders

May 28, 2025 | msn.com

PDS Biotechnology (NASDAQ:PDSB) Raised to Hold at Wall Street Zen

May 26, 2025 | americanbankingnews.com

Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"

May 26, 2025 | marketbeat.com

Q2 EPS Estimates for PDS Biotechnology Increased by B. Riley

May 24, 2025 | marketbeat.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of ...

May 23, 2025 | uk.finance.yahoo.com

B. Riley Increases Earnings Estimates for PDS Biotechnology

May 23, 2025 | americanbankingnews.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025 | globenewswire.com

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses

May 16, 2025 | uk.investing.com

Data and sensing technology: Increases the value of PDS

May 16, 2025 | miningreview.com

PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

May 15, 2025 | finance.yahoo.com

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

EMV Capital portfolio company PDS Biotech advances cancer trial

May 15, 2025 | proactiveinvestors.co.uk

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 14, 2025 | globenewswire.com

Insights Ahead: PDS Biotechnology's Quarterly Earnings

May 14, 2025 | benzinga.com

PDS Biotechnology (PDSB) to Release Earnings on Wednesday

May 11, 2025 | marketbeat.com

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025 | globenewswire.com

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 8, 2025 | globenewswire.com

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CEMI, PDSB, ASRT, and CLSD Company Descriptions

Assertio NASDAQ:ASRT

$0.66 -0.01 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.01 (+1.89%)

As of 04:32 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Chembio Diagnostics NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Clearside Biomedical NASDAQ:CLSD

$0.74 -0.02 (-2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.75 +0.01 (+1.64%)

As of 05:24 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

PDS Biotechnology NASDAQ:PDSB

$1.41 +0.03 (+2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 +0.01 (+0.71%)

As of 05:19 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time